Business briefs: Bayer; Mylan

Share this article:

Bayer released its annual report and fourth quarter earnings today. The German drugmaker's earnings before interest, taxes, depreciation, amortization, and special items increased 18% to €1.83 billion, besting average Bloomberg analyst estimates of €1.81 billion. The company also raised sales forecasts for 2013, estimating a 4-5% gain. Bayer said marketing new drugs will receive a greater focus this year, particularly Xarelto, the blood-thinner it sells with J&J, and Stivarga, a cancer drug for patients with rare kind of stomach tumor. Sales of Xarelto quadrupled last year to €131 million per quarter. However, settlement and legal expenses for contraceptives Yasmin and Yaz over alleged cardiovascular incidents set the drugmaker back a whopping €1.19 billion for the year.

Mylan has acquired Strides Arcolab's Indian injectable manufacturer Agila Specialites for $1.6 billion. The move will expand Mylan's presence into emerging markets like Brazil (where Agila has an antibiotics facility) and add 200 marketable products to its portfolio, leaving Mylan with a total of 700. Heather Bresch, CEO, announced the company's plan to become “a top-three global player” in injectables. Agila currently has 350 products in various stages of development, along with seven manufacturing plants. Leerink Swann analyst Jason Gerberry estimates the acquisition will add 4% to Mylan's 2014 earnings.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.